An anti-inflammatory and anti-aging cosmetic that can be used after medical aesthetics

Abstract

The present invention discloses an anti-inflammatory and anti-aging cosmetic that can be used after medical aesthetics, belonging to the field of cosmetics. Specifically, it relates to a liquid complex, which is prepared from an active agent, an adjuvant and water, and can be used in cosmetics. The adjuvant also includes a thickener, a humectant and a preservative. The active agent in the present invention at least includes an active substance, and the active substance includes at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE liposome, bifidobacterium ferment lysate and lysate. An active agent can also be added to the active agent in the present invention. The liquid complex obtained by the present invention has the effects of no cytotoxicity, good safety, promoting cell proliferation, good anti-inflammatory effect, good anti-aging effect, no irritation to the skin, and good anti-inflammatory effect after medical aesthetics.

Description

Technical Field

[0001] The invention belongs to the field of cosmetics, and in particular relates to an anti-inflammatory and anti-aging cosmetic that can be used after medical aesthetics. Background Art

[0002] With people's constant pursuit of beauty, the field of medical cosmetology has ushered in unprecedented development opportunities. Various minimally invasive beauty technologies have sprung up, among which mesodermal beauty, photoelectric beauty and other technologies are favored for their remarkable effects. These technologies effectively solve a series of problems such as skin spots, aging, acne and dryness through different mechanisms of action, making the skin glow. However, while bringing beauty, minimally invasive medical beauty surgery will inevitably have a certain impact on the skin barrier. As an important protective layer of the human body, once damaged, the skin barrier will not only affect the health of the skin, but also may cause the emergence of various skin problems. For some patients with sensitive skin, the harm caused by the release of inflammatory factors during the repair process is more lasting. Therefore, after minimally invasive medical beauty surgery, the use of barrier repair products has become an indispensable part. At the same time, inflamed skin is more susceptible to external stimuli than normal skin, inducing inflammation, releasing free radicals to participate in the inflammation and glycation process, forming a vicious cycle of inflammation-glycation-oxidation, and making the skin more susceptible to aging. Therefore, the anti-aging effect on inflamed skin is as important as anti-inflammatory repair. However, the Class II dressings commonly used after medical aesthetics mainly play the role of physical barriers by forming a protective layer on the wound surface. CN117085174A discloses a liquid dressing for wound care after medical aesthetics and its preparation method, but the Class II dressing does not have pharmacological effects and cannot be degraded and absorbed. It can only limit the use of macromolecular moisturizing substances and cannot be truly absorbed through the skin. After the skin wound heals quickly, the therapeutic effect of Class II dressings is no longer significant. Conventional cosmetics with anti-aging effects lack research on the population suitable for the inflammatory period after medical aesthetics.

[0003] The repair process after aesthetic medicine can be divided into three stages. The acute inflammatory stage within 24 hours after surgery. Within minutes of tissue injury, immune cells rapidly infiltrate the wound. Neutrophils and macrophages are the main effector cells during the inflammatory stage. These immune cells release various cytokines and chemokines, recruiting cells from the blood and the edge of the injury into the local wound. At the same time, the secreted cytokines can further promote the proliferation of cells at the injury site. In addition, immune cells secrete various proteases and reactive oxygen species to resist the invasion of pathogenic microorganisms and remove damaged cells. Although the early inflammatory response is beneficial to wound healing, multiple studies have shown that an increase in the number of local immune cells or an extension of the inflammatory reaction time at the injury site will lead to a disorder in the injury repair process, ultimately resulting in chronic non-healing wounds or the formation of pathological scars. This is mainly because the continuously generated ROS at the injury site destroys the cell structure and function, disrupting the normal skin repair process. New tissue begins to form 2 to 10 days after skin injury, and the repair enters the proliferation stage. This stage mainly includes angiogenesis, granulation tissue formation, and re-epithelialization. Angiogenesis is the key to wound repair. Macrophages and damaged endothelial cells release FGF-2 and VEGF to promote angiogenesis. Subsequently, capillary sprouts infiltrate the injury site, forming granulation tissue with fibroblasts and immune cells, providing nutrients and oxygen for cell metabolism. Finally, growth factors such as EGF and TGF-β stimulate the proliferation and migration of keratinocytes at the edge of the injury, enabling re-epithelialization of the damaged dermis. After the re-epithelialization process is completed, keratinocytes differentiate and the epidermal barrier function is restored. At the same time, dermal fibroblasts proliferate and migrate to the injury site, producing a large amount of extracellular matrix. At the end of this stage, growth factors (TGF-β) or mechanical pressure stimulate some fibroblasts to differentiate into myofibroblasts, and myofibroblasts express actin (α-smooth) to promote wound contraction. The third stage is the tissue remodeling stage, which generally occurs 2 to 3 weeks after injury and can last for many years. During this stage, the signals activated by the injury gradually weaken. Once wound re-epithelialization is completed, keratinocytes stop proliferating and migrating and then begin to differentiate. The blood vessels in the newly formed tissue gradually mature, forming a functional network. Most endothelial cells, inflammatory cells, fibroblasts, and myofibroblasts undergo apoptosis or withdraw from the wound. The granulation tissue formed during the early repair process is gradually replaced by the newly formed collagen-rich dermal matrix. It should be noted that normal skin tissue is mainly composed of a basket-weaving structure formed by type III collagen, while the injured site is remodeled into coarser type I collagen and forms a dense parallel structure. Epidermal appendages such as hair follicles and sebaceous glands generally cannot regenerate during this process. Therefore, the newly formed tissue is usually different from healthy tissue, presenting as a scar, mainly characterized by a decrease in elasticity and tensile strength. Summary of the Invention

[0004] Combining the usage scenarios and functional deficiencies of Class II excipients and conventional cosmetics, the present invention proposes the concept of a combination of cosmetics and medical devices. During the polar inflammatory period after medical aesthetics, Class II sterile dressing products are used to inhibit the occurrence of acute inflammation and promote wound healing. Subsequently, mild and soothing anti-aging products are used to meet the anti-aging needs.

[0005] The purpose of the present invention is to provide an anti-inflammatory and anti-aging cosmetic for use after medical aesthetics, which has no cytotoxicity, good safety, promotes cell proliferation, has good anti-inflammatory effects, good anti-aging effects, is non-irritating to the skin, and has good anti-inflammatory effects after medical aesthetics.

[0006] The technical solution adopted by the present invention to achieve the above purpose is as follows:

[0007] A liquid complex, comprising: an active agent and water, wherein the content of the active agent in the liquid complex is 0.003 - 6.0 wt%; the active agent includes an active substance, and the active substance includes at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, palmitoyl tripeptide-5, ACE liposome, bifidobacterium ferment lysate, and cytolysate. The liquid complex in the present invention is a product with both anti-inflammatory and anti-aging effects, which can be used for daily skin care and after medical aesthetics. It can not only make up for the anti-aging effect of Class II dressings but also meet the mild anti-inflammatory effect of cosmetics. The formula components are simple and the process operation is convenient.

[0008] Preferably, the liquid complex further includes a thickener, and the thickener includes at least one of carbomer, xanthan gum, and sclerotium gum, and the content of the thickener in the liquid complex is 0.01 - 1.0 wt%.

[0009] Preferably, the liquid complex further includes a humectant, and the humectant includes at least one of glycerin, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, carboxymethyl cellulose, and chitosan, and the content of the humectant in the liquid complex is 1 - 20 wt%.

[0010] Preferably, the liquid complex further includes a preservative, and the preservative is a raspberry ketone system, and the content of the preservative in the liquid complex is 0.1 - 1.0 wt%.

[0011] Preferably, the active agent further includes an active ingredient, and the active ingredient includes a succinate derivative, which is made from 2-aminoethanol hydrogen sulfate and maleate, and the maleate is made from trimethylolpropane and maleic anhydride. The present invention discovers that the succinate derivative can be used in combination with the active substance, and under the action of other adjuvants, the anti-aging and anti-inflammatory effects of the obtained liquid complex can be improved, with no cytotoxicity, good safety, and no irritation to the skin.

[0012] More preferably, the content of the active ingredient in the liquid complex is 0.003 - 1.0 wt%; or,

[0013] The content of the active ingredient in the liquid complex is 0.003 - 5.0 wt%.

[0014] More preferably, in the preparation of the maleate, trimethylolpropane and maleic anhydride are mixed and reacted to obtain the maleate, and the usage amount of trimethylolpropane is 50 - 150 wt% of maleic anhydride.

[0015] More preferably, in the preparation of the succinate derivative, 2 - aminoethanol hydrogen sulfate and the maleate are mixed in an aqueous ethanol solution containing sodium hydroxide and reacted to obtain the succinate derivative; the usage amount of 2 - aminoethanol hydrogen sulfate is 20 - 30 wt% of the maleate.

[0016] The present invention discloses the use of the above - mentioned liquid complex in the preparation of anti - inflammatory cosmetics and / or anti - aging cosmetics and / or non - irritating products.

[0017] Preferably, in the preparation of the maleate, at 60 - 80 °C, trimethylolpropane is added to maleic anhydride and reacted at 85 - 95 °C for 2 - 8 h. After the reaction is completed, the maleate is obtained.

[0018] More preferably, in the preparation of the maleate, the usage amount of trimethylolpropane is 50 - 150 wt% of maleic anhydride.

[0019] Preferably, in the preparation of the succinate derivative, sodium hydroxide and 2 - aminoethanol hydrogen sulfate are added to deionized water, stirred and mixed, then at 30 - 50 °C, the maleate and ethanol are added and reacted for 2 - 8 h. After the reaction is completed, it is cooled to precipitate, filtered, washed, and distilled under reduced pressure to obtain the succinate derivative.

[0020] More preferably, in the preparation of the succinate derivative, the usage amount of sodium hydroxide is 30 - 50 wt% of deionized water.

[0021] More preferably, in the preparation of the succinate derivative, the usage amount of 2 - aminoethanol hydrogen sulfate is 40 - 60 wt% of deionized water.

[0022] More preferably, in the preparation of the succinate derivative, the usage amount of 2 - aminoethanol hydrogen sulfate is 20 - 30 wt% of the maleate.

[0023] More preferably, in the preparation of the succinate derivative, the usage amount of absolute ethanol is 100 - 200 wt% of the maleate.

[0024] The present invention discloses a preparation method of a liquid complex, comprising: adding a thickening agent into water, then adding a humectant and a preservative, performing a homogenization treatment at 70 - 90 °C for 2 - 10 min, after the homogenization treatment is completed, cooling to 20 - 50 °C, then adding an active agent, stirring and mixing evenly, and cooling to room temperature to obtain the liquid complex.

[0025] Preferably, the active agent includes an active substance, and the active substance includes at least one of acetyl hexapeptide - 8, oligopeptide - 1, snake venom - like peptide, carnosine, palmitoyl tripeptide - 1, ACE liposome, bifidobacterium ferment lysate, and cytolysate. The content of the active substance in the liquid complex is 0.003 - 5.0 wt%.

[0026] Preferably, the thickening agent includes at least one of carbomer, xanthan gum, and sclerotium gum. The content of the thickening agent in the liquid complex is 0.01 - 1.0 wt%.

[0027] Preferably, the humectant includes at least one of glycerol, 1,2 - pentanediol, dipropylene glycol, carboxymethyl cellulose, and chitosan. The content of the humectant in the liquid complex is 1 - 20 wt%.

[0028] Preferably, the preservative is a raspberry ketone system. The content of the preservative in the liquid complex is 0.1 - 1.0 wt%.

[0029] Preferably, the balance of the reagents in the liquid complex is water.

[0030] Preferably, the active agent further includes an active ingredient. The content of the active ingredient in the liquid complex is 0.003 - 1.0 wt%. The active ingredient includes a succinate derivative and / or propylene glycol alginate. The present invention can also add propylene glycol alginate as an active ingredient. Using propylene glycol alginate and a succinate derivative as active ingredients, under the action of the active substance and adjuvants, the obtained liquid complex has better anti - aging and anti - inflammatory effects, no cytotoxicity, good safety, and no irritation to the skin.

[0031] More preferably, the active ingredient includes a succinate derivative. The content of the succinate derivative in the liquid complex is 0.003 - 0.5 wt%.

[0032] More preferably, the active ingredient further includes propylene glycol alginate. The content of propylene glycol alginate in the liquid complex is 0.003 - 0.5 wt%.

[0033] Without affecting the effects of the present invention, reagents harmless to the human body, such as EDTA, disodium EDTA, amino acids, etc., can be added to the present invention. The amino acids include amino acids such as arginine.

[0034] Since the present invention uses an active agent, an adjuvant, and water to prepare a liquid complex, it can be used in cosmetics. The adjuvant also includes a thickener, a humectant, and a preservative. The active agent in the present invention at least includes an active substance, and the active substance includes at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE liposome, bifidobacterium ferment lysate, and lysate. The liquid complex containing the above active substances has excellent anti-inflammatory and anti-aging effects. Further, an active agent can be added to the present invention. With the action of the active substance and the adjuvant, the obtained liquid complex has more excellent effects. The liquid complex obtained by the present invention has the effects of no cytotoxicity, good safety, promoting cell proliferation, good anti-inflammatory effect, good anti-aging effect, no irritation to the skin, and good anti-inflammatory effect after medical aesthetics. Therefore, the present invention is an anti-inflammatory and anti-aging cosmetic that can be used after medical aesthetics, which has no cytotoxicity, good safety, promotes cell proliferation, has a good anti-inflammatory effect, has a good anti-aging effect, has no irritation to the skin, and has a good anti-inflammatory effect after medical aesthetics. Description of the Drawings

[0035] Figure 1 It is a diagram of the expression results of cell inflammatory factors.

[0036] Figure 2 It is a diagram of the expression results of cell inflammatory factors.

[0037] Figure 3 It is a diagram of the expression results of cell inflammatory factors.

[0038] Figure 4 It is a diagram of the expression results of cell inflammatory factors.

[0039] Figure 5 It is a diagram of the expression of the inflammatory factor MIF.

[0040] Figure 6 It is a diagram of the results of relative gene expression.

[0041] Figure 7 It is a diagram of the results of relative gene expression.

[0042] Figure 8 It is a diagram of the results of relative gene expression.

[0043] Figure 9 It is a diagram of the results of relative gene expression.

[0044] Figure 10 It is a diagram of the relative gene expression of NFE2L2. Detailed Embodiments

[0045] Next, the technical solutions in the embodiments of the present invention will be clearly and completely described in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0046] First, the concepts involved in the present application will be described in conjunction with the accompanying drawings. It should be noted here that the following descriptions of each concept are only for making the content of the present application easier to understand, and do not represent a limitation on the protection scope of the present application; at the same time, without conflict, the embodiments in the present application and the features in the embodiments can be combined with each other. The present application will be described in detail below with reference to the accompanying drawings and in conjunction with the embodiments.

[0047] Example 1: A preparation method of a liquid complex

[0048] Preparation of the liquid complex: Add a thickening agent to water, then add a humectant and a preservative, homogenize at 80 °C for 3 min. After the homogenization treatment is completed, cool to 40 °C, then add an efficacy agent, stir and mix evenly, and cool to room temperature to obtain the liquid complex. The thickening agent is carbomer, the humectant is glycerol, the preservative is a raspberry ketone system, the efficacy agent includes active substances, and the active substances are ACE liposomes, acetyl hexapeptide-8, syn-ake, and lysate of bifida ferment lysate. The ACE liposomes are Lips-014 ACE liposomes. The content of the thickening agent in the liquid complex is 0.24 wt%; the content of the humectant in the liquid complex is 8 wt%; the content of the preservative in the liquid complex is 0.35 wt%; the content of the ACE liposomes in the liquid complex is 1.5 wt%, the content of acetyl hexapeptide-8 in the liquid complex is 0.005 wt%, the content of syn-ake in the liquid complex is 0.01 wt%, and the content of lysate of bifida ferment lysate in the liquid complex is 1.5 wt%; the balance is water.

[0049] The liquid complex prepared in Example 1: an efficacy agent, a thickener, a humectant, a preservative, and water. The efficacy agent includes an active ingredient, and the active ingredient is ACE liposome, acetyl hexapeptide-8, syn-ake, and lysate of bifidobacterium longum ferment. The ACE liposome is Lips-014 ACE liposome. The content of ACE liposome in the liquid complex is 1.5 wt%, the content of acetyl hexapeptide-8 in the liquid complex is 0.005 wt%, the content of syn-ake in the liquid complex is 0.01 wt%, and the content of lysate of bifidobacterium longum ferment in the liquid complex is 1.5 wt%. The thickener is carbomer, and the content of the thickener in the liquid complex is 0.24 wt%. The humectant is glycerol, and the content of the humectant in the liquid complex is 8 wt%. The preservative is raspberry ketone system, and the content of the preservative in the liquid complex is 0.35 wt%. The balance is water.

[0050] Example 2: A preparation method of a liquid complex

[0051] Compared with Example 1, the difference in this example is that the efficacy agent further includes an active agent. The active agent is a succinate derivative. The content of the succinate derivative in the liquid complex is 0.009 wt%.

[0052] Preparation of maleate: At 70 °C, trimethylolpropane was added to maleic anhydride and reacted at 90 °C for 4 h. After the reaction was completed, maleate was obtained. The usage amount of trimethylolpropane was 100 wt% of maleic anhydride.

[0053] Preparation of succinate derivative: Sodium hydroxide and 2-aminoethanol hydrogen sulfate were added to deionized water and stirred and mixed. Then, maleate and ethanol were added at 40 °C and reacted for 4 h. After the reaction was completed, the mixture was cooled to precipitate, filtered, washed, and distilled under reduced pressure to obtain the succinate derivative. The usage amount of sodium hydroxide was 40 wt% of deionized water, the usage amount of 2-aminoethanol hydrogen sulfate was 50 wt% of deionized water, the usage amount of 2-aminoethanol hydrogen sulfate was 25 wt% of maleate, and the usage amount of absolute ethanol was 150 wt% of maleate.

[0054] The liquid complex prepared in Example 2: an efficacy agent, a thickener, a humectant, a preservative, and water. The efficacy agent includes an active ingredient and an active agent. The active ingredient is ACE liposome, acetyl hexapeptide-8, syn-ake, and lysate of bifidobacterium ferment lysate. The ACE liposome is Lips-014 ACE liposome. The content of ACE liposome in the liquid complex is 1.5 wt%. The content of acetyl hexapeptide-8 in the liquid complex is 0.005 wt%. The content of syn-ake in the liquid complex is 0.01 wt%. The content of lysate of bifidobacterium ferment lysate in the liquid complex is 1.5 wt%. The active agent is a succinate derivative. The content of the succinate derivative in the liquid complex is 0.009 wt%. The thickener is carbomer. The content of the thickener in the liquid complex is 0.24 wt%. The humectant is glycerol. The content of the humectant in the liquid complex is 8 wt%. The preservative is a raspberry ketone system. The content of the preservative in the liquid complex is 0.35 wt%. The balance is water.

[0055] Example 3: A method for preparing a liquid complex

[0056] Compared with Example 1, the difference in this example is that the efficacy agent further includes an active agent. The active agent is a succinate derivative. The content of the succinate derivative in the liquid complex is 0.03 wt%.

[0057] The liquid complex prepared in Example 3: an efficacy agent, a thickener, a humectant, a preservative, and water. The efficacy agent includes an active ingredient and an active agent. The active ingredient is ACE liposome, acetyl hexapeptide-8, syn-ake, and lysate of bifidobacterium ferment lysate. The ACE liposome is Lips-014 ACE liposome. The content of ACE liposome in the liquid complex is 1.5 wt%. The content of acetyl hexapeptide-8 in the liquid complex is 0.005 wt%. The content of syn-ake in the liquid complex is 0.01 wt%. The content of lysate of bifidobacterium ferment lysate in the liquid complex is 1.5 wt%. The active agent is a succinate derivative. The content of the succinate derivative in the liquid complex is 0.03 wt%. The thickener is carbomer. The content of the thickener in the liquid complex is 0.24 wt%. The humectant is glycerol. The content of the humectant in the liquid complex is 8 wt%. The preservative is a raspberry ketone system. The content of the preservative in the liquid complex is 0.35 wt%. The balance is water.

[0058] Example 4: A method for preparing a liquid complex

[0059] Compared with Example 3, the difference in this example is that the active agent further includes algal acid-1,2-propylene glycol ester. The content of algal acid-1,2-propylene glycol ester in the liquid complex is 0.003 wt%.

[0060] Liquid complex prepared in Example 4: efficacy agent, thickener, humectant, preservative and water. The efficacy agent includes an active ingredient and an active agent. The active ingredient is ACE liposome, acetyl hexapeptide-8, syn-ake, and lysate of bifidobacterium ferment lysate. The ACE liposome is Lips-014 ACE liposome. The content of ACE liposome in the liquid complex is 1.5 wt%. The content of acetyl hexapeptide-8 in the liquid complex is 0.005 wt%. The content of syn-ake in the liquid complex is 0.01 wt%. The content of lysate of bifidobacterium ferment lysate in the liquid complex is 1.5 wt%. The active agent is succinate derivative and propylene glycol alginate. The content of succinate derivative in the liquid complex is 0.03 wt%. The content of propylene glycol alginate in the liquid complex is 0.003 wt%. The thickener is carbomer. The content of the thickener in the liquid complex is 0.24 wt%. The humectant is glycerol. The content of the humectant in the liquid complex is 8 wt%. The preservative is raspberry ketone system. The content of the preservative in the liquid complex is 0.35 wt%. The balance is water.

[0061] Example 5: A method for preparing a liquid complex

[0062] Compared with Example 3, the difference in this example is that the active agent further includes propylene glycol alginate. The content of propylene glycol alginate in the liquid complex is 0.01 wt%.

[0063] Liquid complex prepared in Example 5: efficacy agent, thickener, humectant, preservative and water. The efficacy agent includes an active ingredient and an active agent. The active ingredient is ACE liposome, acetyl hexapeptide-8, syn-ake, and lysate of bifidobacterium ferment lysate. The ACE liposome is Lips-014 ACE liposome. The content of ACE liposome in the liquid complex is 1.5 wt%. The content of acetyl hexapeptide-8 in the liquid complex is 0.005 wt%. The content of syn-ake in the liquid complex is 0.01 wt%. The content of lysate of bifidobacterium ferment lysate in the liquid complex is 1.5 wt%. The active agent is succinate derivative and propylene glycol alginate. The content of succinate derivative in the liquid complex is 0.03 wt%. The content of propylene glycol alginate in the liquid complex is 0.01 wt%. The thickener is carbomer. The content of the thickener in the liquid complex is 0.24 wt%. The humectant is glycerol. The content of the humectant in the liquid complex is 8 wt%. The preservative is raspberry ketone system. The content of the preservative in the liquid complex is 0.35 wt%. The balance is water.

[0064] Comparative Example 1: A method for preparing a liquid complex

[0065] This comparative example is different from Example 2 in that the content of the succinate derivative in the liquid complex is 0.001 wt%.

[0066] The liquid complex prepared in Comparative Example 1: efficacy agent, thickener, humectant, preservative and water. The efficacy agent includes active substances and active agents. The active substances are ACE liposomes, acetyl hexapeptide-8, syn-ake, and lysate of bifidobacterium ferment lysate. The ACE liposomes are Lips-014 ACE liposomes. The content of ACE liposomes in the liquid complex is 1.5 wt%. The content of acetyl hexapeptide-8 in the liquid complex is 0.005 wt%. The content of syn-ake in the liquid complex is 0.01 wt%. The content of lysate of bifidobacterium ferment lysate in the liquid complex is 1.5 wt%. The active agent is a succinate derivative, and the content of the succinate derivative in the liquid complex is 0.001 wt%. The thickener is carbomer, and the content of the thickener in the liquid complex is 0.24 wt%. The humectant is glycerol, and the content of the humectant in the liquid complex is 8 wt%. The preservative is a raspberry ketone system, and the content of the preservative in the liquid complex is 0.35 wt%. The balance is water.

[0067] Comparative Example 2: A method for preparing a liquid complex

[0068] This comparative example is different from Example 2 in that no active substances are added to the liquid complex.

[0069] The liquid complex prepared in Comparative Example 1: efficacy agent, thickener, humectant, preservative and water. The efficacy agent includes active agents. The active agent is a succinate derivative, and the content of the succinate derivative in the liquid complex is 0.009 wt%. The thickener is carbomer, and the content of the thickener in the liquid complex is 0.24 wt%. The humectant is glycerol, and the content of the humectant in the liquid complex is 8 wt%. The preservative is a raspberry ketone system, and the content of the preservative in the liquid complex is 0.35 wt%. The balance is water.

[0070] In the selection of the components of the liquid complex in the present invention, without affecting the technical effects of the present invention, any selection can be made among glycerol, disodium EDTA, raspberry ketone, 1,2-hexanediol, xanthan gum, 1,2-pentanediol, carbomer, carboxymethyl chitosan, arginine, dipropylene glycol, ACE liposomes, acetyl hexapeptide-8, syn-ake, oligopeptide-1, palmitoyl tripeptide-5, carnosine, and lysate of bifidobacterium ferment lysate.

[0071] Test Example:

[0072] 1. Cytotoxicity test

[0073] The present invention conducted a cytotoxicity test on the liquid complex prepared in Example 1. The liquid complex of Example 1 was mixed with the culture medium to prepare 8 test groups of liquid complexes with different volume percentages: 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, 0.01953125%; a blank control group and a positive control group were set up. The blank control group was the culture medium, and the positive control group was the culture medium added with 10% DMSO by mass. The test groups, the blank control group, and the positive control group were contacted with the test cells. Through the test of the inhibitory effect on cell growth, the in vitro toxicity effect on the cells was evaluated, and the safety of the base as a human contact material was investigated. The test cells were human immortalized keratinocytes (HaCaT).

[0074] Table 1 Cytotoxicity test results

[0075] Grouping Blank control Positive control Test group 1 Test group 2 Test group 3 Test group 4 Test group 5 Test group 6 Test group 7 Test group 8 Mean 0.8846 0.2446 0.8339 0.8001 0.7761 0.7766 0.7732 0.7505 0.7720 0.7860 SD 2.64% 0.38% 0.52% 0.72% 0.72% 0.74% 0.72% 1.01% 0.66% 0.53% CV 2.99% 1.55% 0.63% 0.90% 0.93% 0.96% 0.93% 1.34% 0.86% 0.67% Survival rate 100% 27.65% 94.27% 90.45% 87.73% 87.79% 87.41% 84.84% 87.27% 88.85% p - value / <0.0001 0.0154 0.0012 0.0003 0.0003 0.0002 0.0001 0.0002 0.0004

[0076] The cytotoxicity test results of the liquid complex prepared in Example 1 of the present invention are shown in Table 1. Among them, the volume percentages of the liquid complexes corresponding to Test Group 1, Test Group 2, Test Group 3, Test Group 4, Test Group 5, Test Group 6, Test Group 7, and Test Group 8 are 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125% respectively; the cell survival rates of the test groups at the volume percentages of 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125% are 94.27%, 90.45%, 87.73%, 87.79%, 87.41%, 84.84%, 87.27%, and 88.85% respectively, all of which are greater than 70%, and the tested liquid complex has no cytotoxicity. The present invention conducted a cytotoxicity test on the succinate derivative prepared in Example 2. The liquid complex was prepared by the preparation method of Example 2, and the succinate derivative in the liquid complex was changed to 1 wt%, and then added to the cell culture medium at a volume percentage of 2.50% of the usage amount of the liquid complex, and the obtained cell survival rate was 92.51%, without cytotoxicity.

[0077] 2. Cell proliferation test

[0078] The present invention conducted a cell proliferation test on the liquid complex prepared in Example 1. The liquid complex of Example 1 was mixed with the culture medium to prepare 8 test groups with different volume percentages of the liquid complex: 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, 0.01953125%; a blank control group and a positive control group were set up. The blank control group was the culture medium, and the positive control group was the culture medium added with 10% DMSO by mass fraction. The test groups, the blank control group, and the positive control group were contacted with the test cells, and the cell proliferation rate of HSF cells was calculated to evaluate the proliferation effect on cells. The test cells were human skin fibroblasts (HSF).

[0079] Table 2 Cell Proliferation Test Results

[0080] Grouping Blank control Positive control Test group 1 Test group 2 Test group 3 Test group 4 Test group 5 Test group 6 Test group 7 Test group 8 Mean 0.4411 0.5488 0.6203 0.6047 0.5569 0.531 0.5007 0.4998 0.4914 0.4274 SD 0.19% 0.95% 0.23% 1.08% 2.78% 1.00% 1.70% 1.65% 1.07% 1.61% CV 0.43% 1.73% 0.37% 1.78% 4.99% 1.89% 3.40% 3.30% 2.17% 3.77% Survival rate 100% 124.42% 140.64% 137.11% 126.25% 120.40% 113.51% 113.31% 111.40% 96.89% p - value / 0 0 0 0.002 0.0001 0.0038 0.0036 0.0013 0.2175

[0081] The cell proliferation test results of the liquid complex prepared in Example 1 of the present invention are shown in Table 2. Among them, the volume percentages of the liquid complexes corresponding to Test Group 1, Test Group 2, Test Group 3, Test Group 4, Test Group 5, Test Group 6, Test Group 7, and Test Group 8 are 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125% respectively; the test groups have a significant cell-promoting proliferation effect on human skin fibroblasts (HSF) at volume percentages of 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125, and 0.0390625%.

[0082] 3. Anti-inflammatory Effect Test

[0083] The present invention used a Luminex 200 liquid-phase suspension chip instrument to detect the expression of inflammatory factors after treating human fibroblasts with the test samples. The present invention used three different test samples to administer to human fibroblasts. After culturing in a 37°C carbon dioxide incubator for 24 h, the supernatant was collected in a new plate, and a protein chip study was conducted to detect the expression level of cell inflammatory factors. In the present invention, the above tests were divided into 4 groups, each group containing 3 replicate wells, namely the negative control group, Test Group 1, Test Group 2, and Test Group 3; the negative control group was added with water, Test Group 1 was the liquid complex prepared in Example 1 at 0.5 vol%, Test Group 2 was a commercially available product 1 at 0.5 vol%, and Test Group 3 was a commercially available product 2 at 0.5 vol%. Commercially available product 1 is Winona Revitalizing Repair Essence, and commercially available product 2 is Helena Rubinstein Green Bottle Series Essence.

[0084] This study detected the expression of a total of 48 inflammatory factors, and the research results are as Figures 1 - 3As shown, a significant analysis was conducted on the results of its 8 inflammatory factors, and the research results are as Figure 4 shown.

[0085] Table 3 Statistical table of significance of inflammatory factors

[0086]

[0087] The statistical significance of the 8 inflammatory factors in the present invention is shown in Table 3. Among them, Test Group 1, Test Group 2, and Test Group 3 all showed a significant ability to down-regulate the expression of CRO-α inflammatory factors. Through in-depth comparative research on three types of skin care essence products, it was found that Test Group 1 had the most significant inhibitory effect on inflammation at 0.5 vol%.

[0088] The present invention conducted an anti-inflammatory test on the liquid complexes prepared in Examples 1-5 and Comparative Examples 1-2, and set a negative control group. The negative control group was water, and a comparative analysis was carried out on the expression of the inflammatory factor of MIF. The results are as Figure 5 shown, where S1 is Example 1, S2 is Example 2, S3 is Example 3, S4 is Example 4, S5 is Example 5, D1 is Comparative Example 1, D2 is Comparative Example 2, and NC is the negative control group. The present invention prepared a liquid complex using an active agent, an adjuvant, and water. The active agent at least includes an active substance, and the adjuvant includes a thickener, a moisturizer, and a preservative. The active substance can be at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE liposome, bifidobacterium ferment lysate, and cytolysate. Through the compounding of the active agent and the adjuvant, the obtained liquid complex has good anti-inflammatory effects; an active agent can also be added to the active agent. The active agent of the present invention can use a succinate derivative, which is made from 2-aminoethanol hydrogen sulfate and maleate, and the maleate is made from trimethylolpropane and maleic anhydride. The use of the succinate derivative, combined with the compounding of the active substance and the adjuvant, results in a liquid complex with better anti-inflammatory ability and a better reduction effect on the relative gene expression level of MIF; with the increase in the usage amount of the succinate derivative, the anti-inflammatory ability of the obtained liquid complex increases, and the relative gene expression level of MIF can be reduced; when the usage amount of the succinate derivative in the active agent is too low, it is impossible to enhance the anti-inflammatory ability of the liquid complex, nor can it reduce the relative gene expression level of MIF; alginate-1,2-propylene glycol ester can also be added to the active agent of the present invention. When alginate-1,2-propylene glycol ester and the succinate derivative are used as active agents together with the active substance and the adjuvant, the obtained liquid complex has better anti-inflammatory ability and a better reduction effect on the relative gene expression level of MIF. If the active substance is not used in the liquid complex and only the active agent is added, the anti-inflammatory ability of the obtained liquid complex is poor, and it is also impossible to significantly reduce the relative gene expression level of MIF.

[0089] 4. Quantitative Gene Expression Test for Anti-aging Effect

[0090] The present invention uses the Luminex 200 suspension chip multiplex detection system technology and combines with the QGP method to detect and analyze the effects of three test samples on gene expression in human fibroblasts. The present invention administers three different test samples to HFF cells, which are seeded in a 24-well plate at a density of 8×10 4 cells per well, and the volume of each well is 0.5 ml. The cell plates are cultured in an incubator for 24 h.

[0091] In the present invention, the above tests are divided into 4 groups, each group contains 3 replicates, which are negative control group, test group 1, test group 4, and test group 5; water is added to the negative control group, test group 1 is the liquid complex prepared in Example 1 at 0.5 vol%, test group 4 is commercial product 3 at 0.5 vol%, and test group 5 is commercial product 4 at 0.5 vol%. Commercial product 1 is Winona Revitalizing Repair Essence, and commercial product 2 is Helena Rubinstein Green Bottle Series Essence. The content is 0.5 vol% for all. After 24 h of culture, after aspirating the supernatant, 0.2 ml of cell lysate is added to the well plate containing HFF cells to lyse the cells. The lysed cells are stored at -80°C. Commercial product 4 is a certain W essence, and commercial product 5 is Helena Rubinstein Green Bottle Series Essence.

[0092] The present invention detected the expression of 41 genes in total. After treating the cells with three test samples, the whole gene results are as Figures 6 - 8 shown. The study performed a significant analysis on eight of these genes, namely COL3A1, COL1A1, FGF7, TIMP2, SOD2, NFE2L2, MMP1, and IL6, and the results are shown in Figure 9 and Table 4.

[0093] Table 4 Results of Significant Analysis of Seven Genes

[0094]

[0095] The test group 1 at 0.5 vol% can significantly up-regulate the relative gene expression levels of COL3A1, COL1A1, and NFE2L2 (p<0.01), can significantly up-regulate the relative gene expression levels of FGF7 and TIMP2 (p<0.05), and can also significantly down-regulate the relative gene expression level of MMP1 (p<0.01); the test group 5 at 0.5 vol% can significantly up-regulate the relative gene expression level of COL1A1 (p<0.01).

[0096] In summary, among the test group 1, test group 4, and test group 5, the test group 1 has a better regulatory effect on aging genes and has significant anti-aging ability.

[0097] The present invention conducts anti-aging tests on the liquid complexes prepared in Examples 1-5 and Comparative Examples 1-2, sets a negative control group, and the negative control group is water. Comparative analysis is carried out based on the relative gene expression level of NFE2L2. The results are as Figure 10 shown, where S1 is Example 1, S2 is Example 2, S3 is Example 3, S4 is Example 4, S5 is Example 5, D1 is Comparative Example 1, D2 is Comparative Example 2, and NC is the negative control group. The present invention uses an active agent, an adjuvant, and water to prepare a liquid complex. The active agent at least includes an active substance, and the adjuvant includes a thickener, a humectant, and a preservative. The active substance can be at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE liposome, bifidobacterium ferment lysate, and lysate. Through the compounding of the active agent and the adjuvant, the obtained liquid complex has good anti-aging effects; an active agent can also be added to the active agent. The active agent of the present invention can use a succinate derivative, and the succinate derivative is made from 2-aminoethanol hydrogen sulfate and maleate, and the maleate is made from trimethylolpropane and maleic anhydride. The use of the succinate derivative, under the compounding of the active substance and the adjuvant, the obtained liquid complex has better anti-aging ability and has a better improvement effect on the relative gene expression level of NFE2L2; with the increase in the usage amount of the succinate derivative, the anti-aging ability of the obtained liquid complex increases, and the relative gene expression level of NFE2L2 can be increased; when the usage amount of the succinate derivative in the active agent is too low, the anti-aging ability of the liquid complex cannot be enhanced, nor can the relative gene expression level of NFE2L2 be increased; alginate-1,2-propylene glycol ester can also be added to the active agent of the present invention. When alginate-1,2-propylene glycol ester and the succinate derivative are used as active agents together with the active substance and the adjuvant, the obtained liquid complex has better anti-aging ability and has a better improvement effect on the relative gene expression level of NFE2L2. If no active substance is used in the liquid complex and only the active agent is added, the anti-aging ability of the obtained liquid complex is poor, and the relative gene expression level of NFE2L2 cannot be significantly increased.

[0098] 5. Human skin patch test

[0099] Taking the "Technical Specifications for Cosmetics Safety" in 2015 as the reference standard, the liquid complex prepared in Example 1 is used as a test product for skin-retaining products to conduct cosmetic irritation evaluation. The test method is the skin patch test, and 30 people randomly distributed aged 18-60 are tested.

[0100] Test method: Put the test sample into the patch tester with a dosage of 0.025 g. Cover the patch tester with the test sample on the flexor side of the forearm of the subject with a non-irritating cloth-based tape. Gently press with the palm to make it evenly adhere to the skin surface for 24 hours. After removing the test patch tester for 30 minutes and waiting for the indentation to disappear, observe the skin reaction. If the result is negative, observe again at 24 hours and 48 hours after the patch test.

[0101] Evaluation criteria:

[0102] Grade 0: Negative reaction;

[0103] Grade 1: Suspected reaction, only with faint erythema;

[0104] Grade 2: Weak positive reaction, with erythema, infiltration, edema, and may have papules;

[0105] Grade 3: Strong positive reaction, with erythema, infiltration, edema, may have papules, and the reaction may exceed the test area;

[0106] Grade 4: Extremely strong positive reaction, with obvious erythema, severe infiltration, edema, confluent herpes, and the reaction exceeds the test area.

[0107] Test results: The skin reactions of all subjects were negative.

[0108] The above test results indicate that the liquid complex prepared by the present invention is mild and non-irritating to the skin as a skin-resident product and is safe to use.

[0109] 6. Anti-inflammatory effect test after aesthetic medicine

[0110] Collect 30 volunteers who have undergone light aesthetic medicine projects such as photon rejuvenation and hydrodermabrasion, with an age range of 20 - 50 years. Use the liquid complex prepared in Example 1 as the test sample 3 days after the operation. After cleaning the face before use, evenly apply the test sample on the face and continuously use it for 28 days. Observe the skin condition on the 0th day, 14th day, and 28th day.

[0111] Test indicators:

[0112] 6.1. TEWL value detection: TEWL refers to the trans-epidermal water loss of the face and the water content of the stratum corneum. The lower the value, the higher the water content of the stratum corneum and the better the skin barrier function; otherwise, it is worse.

[0113] TEWL value: Healthy state (0 - 15), sub-healthy state (15 - 25), diseased state (> 25).

[0114] Table 5 TEWL value detection results

[0115]

[0116] After using the test product for 28 days, the transdermal water loss of the subjects decreased significantly. It shows that after continuous use of the test product, the transdermal water loss has been significantly improved compared with the initial value, and the improvement rate is 12.25%.

[0117] 6.2 Heme value detection: The content of heme in the skin is determined by measuring the reflection of light with a specific wavelength on the human skin. The lower the content value of heme, the lighter the redness.

[0118] Table 6 Heme value detection results

[0119]

[0120] After using the test product for 28 days, the heme content of the subjects decreased significantly. It shows that after continuous use of the test product, the heme has been improved compared with the initial value. The improvement rate is 6.05%.

[0121] 6.3. Adverse reaction feedback during use

[0122] All 30 subjects used the test product as required within the specified time, and no adverse reactions occurred.

[0123] The above-described embodiments and / or implementation manners are only used to illustrate the preferred embodiments and / or implementation manners for realizing the technology of the present invention, and do not impose any formal restrictions on the implementation manners of the technology of the present invention. Any person skilled in the art, without departing from the scope of the technical means disclosed in the content of the present invention, may make some modifications or changes to other equivalent embodiments, but should still be regarded as the same technology or embodiment as the present invention in essence.

[0124] In this article, specific examples are used to elaborate on the principles and implementation manners of the present application. The description of the above embodiments is only used to help understand the method and its core idea of the present application. The above is only the preferred implementation manner of the present application. It should be noted that due to the limited nature of written expression and objectively infinite specific structures, for those of ordinary skill in the art, without departing from the principles of the present application, several improvements, embellishments or changes can be made, or the above technical features can be combined in an appropriate manner; these improvements, embellishments, changes or combinations, or directly applying the inventive concept and technical solution to other occasions without improvement, should all be regarded as the protection scope of the present application.

Claims

1. A liquid composite, comprising: An efficacy agent and water, the content of the efficacy agent in the liquid complex being 0.003 - 6.0 wt%; the efficacy agent includes an active substance, and the active substance includes at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, palmitoyl tripeptide-5, ACE liposome, bifida ferment lysate and lysate; The efficacy agent further includes an active agent, and the active agent includes a succinate derivative and propylene glycol alginate; In the preparation of the succinate derivative, sodium hydroxide and 2-aminoethanol hydrogen sulfate are added to deionized water, stirred and mixed, then maleate and ethanol are added at 30 - 50 °C, and the reaction is carried out for 2 - 8 h. After the reaction is completed, it is cooled to precipitate a solid, filtered, washed, and distilled under reduced pressure to obtain the succinate derivative; the usage amount of sodium hydroxide is 30 - 50 wt% of the deionized water, the usage amount of 2-aminoethanol hydrogen sulfate is 40 - 60 wt% of the deionized water, the usage amount of 2-aminoethanol hydrogen sulfate is 20 - 30 wt% of the maleate, and the usage amount of absolute ethanol is 100 - 200 wt% of the maleate; In the preparation of the maleate, trimethylolpropane is added to maleic anhydride at 60 - 80 °C, and the reaction is carried out at 85 - 95 °C for 2 - 8 h. After the reaction is completed, the maleate is obtained; the usage amount of trimethylolpropane is 50 - 150 wt% of the maleic anhydride; The content of the active agent in the liquid complex is 0.003 - 1.0 wt%; or, the content of the active substance in the liquid complex is 0.003 - 5.0 wt%.

2. The liquid composite according to claim 1, wherein: The liquid complex further includes a thickener, and the thickener includes at least one of carbomer, xanthan gum and sclerotium gum, and the content of the thickener in the liquid complex is 0.01 - 1.0 wt%.

3. The liquid composite according to claim 1, wherein: The liquid complex further includes a humectant, and the humectant includes at least one of glycerol, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, carboxymethyl cellulose and chitosan, and the content of the humectant in the liquid complex is 1 - 20 wt%.

4. The liquid composite according to claim 1, characterized in that: The liquid complex further includes a preservative, and the preservative is a raspberry ketone system, and the content of the preservative in the liquid complex is 0.1 - 1.0 wt%.

5. Use of a liquid complex according to any one of claims 1 - 4 in the preparation of an anti-inflammatory cosmetic and / or an anti-aging cosmetic and / or a non-irritating product.

6. The use according to claim 5, wherein: The liquid complex further contains at least one of EDTA, disodium EDTA and amino acids.

Images